BINV — BioInvent International AB Share News
0.000.00%
Last trade - 00:00- SEK1.33bn
- SEK1.01bn
- SEK226.50m
Brief: Bioinvent Announces Achievement In Collaboration With Exelixis, Gets USD 1 Mln Payment
Brief: Bioinvent: Phase 1 Study Part B, I.E. Bt-001 In Combination With Pembrolizumab To Start In H2
Brief: Bioinvent Reports Interim Safety Data, Early Signs Of Efficacy In Phase 1/2A Trial
Brief: BioInvent Announces Additional Efficacy Data From Phase 1/2 Trial With BI-1206 In Solid Tumors
Brief: Bioinvent Gets IND Approval For Clinical Trial
Brief: Transgene, BioInvent Report Positive Phase Ia Data On Oncolytic Virus BT-001 In Solid Tumours
Brief: BioInvent, Transgene Report Positive Phase 1a Data On Oncolytic Virus Bt-001 In Solid Tumors
Brief: Bioinvent Gets Patent In Japan Relating To Treatment Of Tumors
Brief: BioInvent Q4 Loss After Tax Unchanged At SEK 78.3 Mln
Brief: BioInvent International Gets $3 Mln Capital Equity Investment
Brief: BioInvent Receives Notice Of Allowance In US For Patent Covering Bi-1206, Bi-1607
Brief: BioInvent Gets FDA Ind Approval For Anti-Fcyriib Antibody BI-1607
Brief: Bioinvent Q3 Loss After Tax Widens To SEK 63.9 Million
Brief: Bioinvent Completes Planned Dose-Escalation
Brief: Bioinvent Q2 Profit After Tax At SEK 167.4 Mln
Brief: BioInvent, Transgene Announce Collaboration And Supply Agreement With MSD
Brief: Transgene And BioInvent Announce Positive Progress For BT-001
Brief: Bioinvent’S BI-1206 To Advance Into Expansion Stage Of Phase 1/2A Study In NHL
Brief: BioInvent Gets Milestone Payment From Bayer/Hope Medicine Licensing Agreement